StockNews.AI
NVO
StockNews.AI
173 days

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

1. Novo Nordisk's Annual General Meeting is on March 27, 2024. 2. Shareholders can participate in-person or virtually via IT applications. 3. Board of Directors proposes re-election of key leaders. 4. Novo Nordisk focuses on addressing chronic diseases and diabetes. 5. Company employs 76,300 and operates in 170 countries.

4m saved
Insight
Article

FAQ

Why Neutral?

The AGM's announcements typically have no immediate price impact historically.

How important is it?

While AGMs can signal shareholder confidence, immediate stock movements are unpredictable.

Why Short Term?

Short-term focus due to the upcoming AGM, but limited stock price movement expected.

Related Companies

NVONovo-B
Bagsværd, Denmark, 27 February 2025 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 27 March 2024 at 14.00 (CET) The Annual General Meeting is held as a partially electronic general meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark or participating virtually via an IT application. We encourage shareholders to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting. Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk’s website. Please refer to the enclosed notice for the Annual General Meeting for further information. BOARD OF DIRECTORSAll Board members elected by the Annual General Meeting are up for election. The Board of Directors proposes re-election of Helge Lund as chair of the Board and re-election of Henrik Poulsen as vice chair. Moreover, the Board proposes re-election of the following Board members: Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Kasim Kutay, Christina Law and Martin Mackay as members of the Board. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@novonordisk.comLiz Skrbkova (US)+1 609 917 0632lzsk@novonordisk.comInvestors: Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.comIda Schaap Melvold +45 3077 5649idmg@novonordisk.comSina Meyer +45 3079 6656azey@novonordisk.comMax Ung+45 3077 6414 mxun@novonordisk.com Frederik Taylor Pitter +1 609 613 0568fptr@novonordisk.com  Company announcement No 10 / 2025 CA250227-AGM-notice-combined

Related News